Taiwan Scientists Test Protein Enabling Colorectal, Cervical Cancers
This article was originally published in PharmAsia News
Executive Summary
Tawainese researchers are testing an adaptor protein that causes cancer as a likely target for treating colorectal, cervical and possibly other cancers. The scientific team said the Eps8 protein had been linked to colorectal cancer two years ago, and then to cervical cancer, but now the researchers believe it enhances the proliferation of cells associated with the two cancers. By lowering the level of Eps8 in animals, the team achieved a decrease in tumor growth. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.